Cargando…

An Explorative Biomarker Study for Vaccine Responsiveness after a Primary Meningococcal Vaccination in Middle-Aged Adults

INTRODUCTION: Prevention of infectious diseases in the elderly is essential to establish healthy aging. Yet, immunological aging impairs successful vaccination of the elderly. Predictive biomarkers for vaccine responsiveness in middle-aged adults may help to identify responders and non-responders be...

Descripción completa

Detalles Bibliográficos
Autores principales: van der Heiden, Marieke, Berbers, Guy A. M., Fuentes, Susana, van Zelm, Menno C., Boots, Annemieke M. H., Buisman, Anne-Marie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5768620/
https://www.ncbi.nlm.nih.gov/pubmed/29375578
http://dx.doi.org/10.3389/fimmu.2017.01962
_version_ 1783292734470094848
author van der Heiden, Marieke
Berbers, Guy A. M.
Fuentes, Susana
van Zelm, Menno C.
Boots, Annemieke M. H.
Buisman, Anne-Marie
author_facet van der Heiden, Marieke
Berbers, Guy A. M.
Fuentes, Susana
van Zelm, Menno C.
Boots, Annemieke M. H.
Buisman, Anne-Marie
author_sort van der Heiden, Marieke
collection PubMed
description INTRODUCTION: Prevention of infectious diseases in the elderly is essential to establish healthy aging. Yet, immunological aging impairs successful vaccination of the elderly. Predictive biomarkers for vaccine responsiveness in middle-aged adults may help to identify responders and non-responders before reaching old age. Therefore, we aimed to determine biomarkers associated with low and high responsiveness toward a primary vaccination in middle-aged adults, for which a tetravalent meningococcal vaccine was used as a model. METHODS: Middle-aged adults (50–65 years of age, N = 100), receiving a tetravalent meningococcal vaccination, were divided into low and high responders using the functional antibody titers at 28 days postvaccination. A total of 48 parameters, including absolute numbers of immune cells and serum levels of cytokines and biochemical markers, were determined prevaccination in all participants. Heat maps and multivariate redundancy analysis (RDA) were used to reveal immune phenotype characteristics and associations of the low and high responders. RESULTS: Several significant differences in prevaccination immune markers were observed between the low and high vaccine responders. Moreover, RDA analysis revealed a significant association between the prevaccination immune phenotype and vaccine responsiveness. In particular, our analysis pointed at high numbers of CD4 T cells, especially naïve CD4 and regulatory T subsets, to be associated with low vaccine responsiveness. In addition, low responders showed lower prevaccination IL-1Ra levels than high responders. CONCLUSION: This explorative biomarker study shows associations between the prevaccination immune phenotype and vaccine responsiveness after a primary meningococcal vaccination in middle-aged adults. Consequently, these results provide a basis for predictive biomarker discovery for vaccine responsiveness that will require validation in larger cohort studies.
format Online
Article
Text
id pubmed-5768620
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-57686202018-01-26 An Explorative Biomarker Study for Vaccine Responsiveness after a Primary Meningococcal Vaccination in Middle-Aged Adults van der Heiden, Marieke Berbers, Guy A. M. Fuentes, Susana van Zelm, Menno C. Boots, Annemieke M. H. Buisman, Anne-Marie Front Immunol Immunology INTRODUCTION: Prevention of infectious diseases in the elderly is essential to establish healthy aging. Yet, immunological aging impairs successful vaccination of the elderly. Predictive biomarkers for vaccine responsiveness in middle-aged adults may help to identify responders and non-responders before reaching old age. Therefore, we aimed to determine biomarkers associated with low and high responsiveness toward a primary vaccination in middle-aged adults, for which a tetravalent meningococcal vaccine was used as a model. METHODS: Middle-aged adults (50–65 years of age, N = 100), receiving a tetravalent meningococcal vaccination, were divided into low and high responders using the functional antibody titers at 28 days postvaccination. A total of 48 parameters, including absolute numbers of immune cells and serum levels of cytokines and biochemical markers, were determined prevaccination in all participants. Heat maps and multivariate redundancy analysis (RDA) were used to reveal immune phenotype characteristics and associations of the low and high responders. RESULTS: Several significant differences in prevaccination immune markers were observed between the low and high vaccine responders. Moreover, RDA analysis revealed a significant association between the prevaccination immune phenotype and vaccine responsiveness. In particular, our analysis pointed at high numbers of CD4 T cells, especially naïve CD4 and regulatory T subsets, to be associated with low vaccine responsiveness. In addition, low responders showed lower prevaccination IL-1Ra levels than high responders. CONCLUSION: This explorative biomarker study shows associations between the prevaccination immune phenotype and vaccine responsiveness after a primary meningococcal vaccination in middle-aged adults. Consequently, these results provide a basis for predictive biomarker discovery for vaccine responsiveness that will require validation in larger cohort studies. Frontiers Media S.A. 2018-01-11 /pmc/articles/PMC5768620/ /pubmed/29375578 http://dx.doi.org/10.3389/fimmu.2017.01962 Text en Copyright © 2018 van der Heiden, Berbers, Fuentes, van Zelm, Boots and Buisman. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
van der Heiden, Marieke
Berbers, Guy A. M.
Fuentes, Susana
van Zelm, Menno C.
Boots, Annemieke M. H.
Buisman, Anne-Marie
An Explorative Biomarker Study for Vaccine Responsiveness after a Primary Meningococcal Vaccination in Middle-Aged Adults
title An Explorative Biomarker Study for Vaccine Responsiveness after a Primary Meningococcal Vaccination in Middle-Aged Adults
title_full An Explorative Biomarker Study for Vaccine Responsiveness after a Primary Meningococcal Vaccination in Middle-Aged Adults
title_fullStr An Explorative Biomarker Study for Vaccine Responsiveness after a Primary Meningococcal Vaccination in Middle-Aged Adults
title_full_unstemmed An Explorative Biomarker Study for Vaccine Responsiveness after a Primary Meningococcal Vaccination in Middle-Aged Adults
title_short An Explorative Biomarker Study for Vaccine Responsiveness after a Primary Meningococcal Vaccination in Middle-Aged Adults
title_sort explorative biomarker study for vaccine responsiveness after a primary meningococcal vaccination in middle-aged adults
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5768620/
https://www.ncbi.nlm.nih.gov/pubmed/29375578
http://dx.doi.org/10.3389/fimmu.2017.01962
work_keys_str_mv AT vanderheidenmarieke anexplorativebiomarkerstudyforvaccineresponsivenessafteraprimarymeningococcalvaccinationinmiddleagedadults
AT berbersguyam anexplorativebiomarkerstudyforvaccineresponsivenessafteraprimarymeningococcalvaccinationinmiddleagedadults
AT fuentessusana anexplorativebiomarkerstudyforvaccineresponsivenessafteraprimarymeningococcalvaccinationinmiddleagedadults
AT vanzelmmennoc anexplorativebiomarkerstudyforvaccineresponsivenessafteraprimarymeningococcalvaccinationinmiddleagedadults
AT bootsannemiekemh anexplorativebiomarkerstudyforvaccineresponsivenessafteraprimarymeningococcalvaccinationinmiddleagedadults
AT buismanannemarie anexplorativebiomarkerstudyforvaccineresponsivenessafteraprimarymeningococcalvaccinationinmiddleagedadults
AT vanderheidenmarieke explorativebiomarkerstudyforvaccineresponsivenessafteraprimarymeningococcalvaccinationinmiddleagedadults
AT berbersguyam explorativebiomarkerstudyforvaccineresponsivenessafteraprimarymeningococcalvaccinationinmiddleagedadults
AT fuentessusana explorativebiomarkerstudyforvaccineresponsivenessafteraprimarymeningococcalvaccinationinmiddleagedadults
AT vanzelmmennoc explorativebiomarkerstudyforvaccineresponsivenessafteraprimarymeningococcalvaccinationinmiddleagedadults
AT bootsannemiekemh explorativebiomarkerstudyforvaccineresponsivenessafteraprimarymeningococcalvaccinationinmiddleagedadults
AT buismanannemarie explorativebiomarkerstudyforvaccineresponsivenessafteraprimarymeningococcalvaccinationinmiddleagedadults